8-15-2017

Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease

Sudipta Pal  
*Melaka Manipal Medical College*

Ruchita Dixit  
*Melaka Manipal Medical College*

Soe Moe  
*Melaka Manipal Medical College*

Myron A. Godinho  
*Manipal University*

Adinegara B.L. Abas  
*Melaka Manipal Medical College*

*See next page for additional authors*

Let us know how access to this document benefits you

Follow this and additional works at: [https://jdc.jefferson.edu/cardeza_foundation](https://jdc.jefferson.edu/cardeza_foundation)

Part of the [Hematology Commons](https://jdc.jefferson.edu/cardeza_foundation)

Recommended Citation

Pal, Sudipta; Dixit, Ruchita; Moe, Soe; Godinho, Myron A.; Abas, Adinegara B.L.; Ballas, Samir K.; Ram, Shanker; and Yousuf, Uduman A.M., "Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease" (2017). *Cardeza Foundation for Hematologic Research*. Paper 44.

[https://jdc.jefferson.edu/cardeza_foundation/44](https://jdc.jefferson.edu/cardeza_foundation/44)
Authors
Sudipta Pal, Ruchita Dixit, Soe Moe, Myron A. Godinho, Adinegara B.L. Abas, Samir K. Ballas, Shanker Ram,
and Uduman A.M. Yousuf

This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/cardeza_foundation/44
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease (Protocol)

Pal S, Dixit R, Moe S, Godinho MA, Abas ABL, Ballas SK, Ram S, Yousuf UAM

Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease.
DOI: 10.1002/14651858.CD012762.
www.cochranelibrary.com
Transcutaneous electrical nerve stimulation (TENS) for pain management in sickle cell disease

Sudipta Pal¹, Ruchita Dixit¹, Soe Moe², Myron A Godinho³, Adinegara BL Abas¹, Samir K Ballas⁴, Shanker Ram⁵, Uduman Ali M Yousuf⁶

¹Department of Community Medicine, Melaka-Manipal Medical College, Melaka, Malaysia. ²Department of Community Medicine, Faculty of Medicine, Melaka, Malaysia. ³Public Health Evidence South Asia (PHESA), Manipal University, Manipal, India. ⁴Cardeza Foundation for Hematologic Research, Department of Medicine, Jefferson Medical College, Thomas Jefferson University, Philadelphia, USA. ⁵Department of Psychiatry, Melaka Manipal Medical College, Melaka, Malaysia. ⁶Department of Medicine, Melaka Manipal Medical College, Melaka, Malaysia

Contact address: Sudipta Pal, Department of Community Medicine, Melaka-Manipal Medical College, Jalan Batu Hampar, Bukit Baru, Melaka, 75150, Malaysia. sudipta_paul@yahoo.com.

Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group.


Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:

To assess the effects of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both), along with any possible adverse effects.

BACKGROUND

Description of the condition

Please refer to the glossary for the explanation of clinical terms (Appendix 1).

Sickle cell disease (SCD) encompasses a host of genetically inherited disorders in which red blood cells become increasingly deformed and friable, causing vaso-occlusion and haemolysis. This disease is one of the most common, severe, single gene mutation (monogenic) disorders (Weatherall 2001).

The disease is most prevalent in sub-Saharan Africa, affecting an estimated 230,000 children born regionally every year - accounting for 80% of the total global incidence (David 2010). In the USA, it affects around 100,000 people, predominantly those of African descent. The disease occurs in about one in every 500 African-American births and one in every 1000 to 1400 Hispanic-American births. Approximately two million Americans, or one in 12 African Americans, carry the sickle cell allele (WHO 2015).

This geographical predominance corresponds to an adaptive advantage: heterozygous carriers (sickle cell trait) are naturally resistant to infection by the endemic Plasmodium falciparum (P falciparum) malarial parasite (Barbedo 1974).

The vaso-occlusive crisis (VOC) is the hallmark of the disease and is often unpredictable, varies in quality, duration, location and severity, and can be precipitated by known and unknown
factors (Ballas 2005). Vaso-occlusive pain episodes are the most common cause of recurrent morbidity, hospital admissions and work or school absenteeism in people with SCD (Platt 1991). Approximately 90% of hospital admissions of people with SCD are for treating acute pain (Brozovic 1987). Hypoxia, dehydration, acidosis, cold exposure and strenuous exercise also can lead to sickling of red blood cells leading to an acute painful episode.

Nociceptive sickle cell pain may be acute recurrent painful crises, chronic pain syndromes and neuropathic pain. The acute painful crisis evolves through prodromal, initial, established and resolving phases (Ballas 2012). Chronic sickle cell pain may be due to avascular necrosis and leg ulcers or intractable pain without any obvious signs. Chronic pain is usually associated with emotional distress, behavioural dysfunction, family stress, financial concern, frequent visits to healthcare providers, heavy use of analgesic medications and fear (Ballas 2005).

Treatment aims for SCD are to relieve pain, prevent infections and manage complications (Stinson 2003). Despite being the main source of discomfort for people with SCD, therapies for pain crises are not definitive. Pharmacotherapies involve opioids, non-opioids and adjuvants. Non-opioids (e.g. acetaminophen, nonsteroidal anti-inflammatory drugs (NSAIDs) tramadol and corticosteroids) have a ‘ceiling effect’ beyond which they are no longer effective, and NSAIDs and corticosteroids have well-known complications such as haemostasis, acute renal failure, congestive heart failure when overused (Niscola 2009). Thus opioids are frequently employed, as they have fewer systemic effects. However, their use is plagued with reports of addiction, tolerance and drug-seeking behaviour (Neville 2011). Moreover, opioids may contribute to the development of acute chest syndrome during an acute sickle cell pain crisis (Buchanan 2005).

These factors have motivated clinicians and researchers worldwide to embrace a multidisciplinary approach towards pain management in people with SCD, with a focus on including non-pharmacological interventions. According to the recommendations of the American Pain Society, pharmacological treatments for SCD should be complimented by psychological, behavioral, and physical modalities (American Pain Society Guidelines 1999).

How the intervention might work
A variety of mechanisms for the analgesic action of TENS have been suggested, including presynaptic inhibition in the dorsal horn of the spinal cord, endogenous pain control via endorphins, and direct inhibition of nerve excitation and restoration ofafferent input (Kaye 2015). This produces a host of responses, including sensation, movement (muscle contraction), and pain relief. In people with SCD, vaso-occlusion leads to secondary tissue injury which generates several major pain mediators like interleukin-1, bradykinin which in turn sensitize peripheral nerve endings and facilitate the transmission of painful stimuli along A-δ and C fibres that reach the cerebral cortex via the spinal cord and the thalamus (Ballas 2005). This partly corresponds to the ‘gate control theory’ (Melzack 1965) for the mechanism of analgesia produced by TENS where the ‘open gate’ between C fibres and T cells which allow pain transmission centrally is closed by the electrical stimulation to the skin provided by the TENS instrument.
**Why it is important to do this review**

Over recent years, although considerable knowledge has been gained on the pathophysiological mechanisms of pain and the pharmacogenetics of analgesics (including opioids) there has been not much progress in the clinical management of sickle cell pain. Many adults with SCD still face accusations, assumptions and disbelief about their painful condition which is often wrongly perceived by some healthcare providers as drug-seeking behaviour (Ballas 2014). Mismanagement of pain in SCD may lead to serious psychosocial and physiological consequences, such as depression, low self esteem, anxiety and reduced participation in social activities, resulting in chronic pain interspersed with episodes of acute exacerbations (Smith 2005). Hence, organizations such as the American Pain Society recommended that pharmacologic treatment for SCD should be complemented by complementary and alternative medicine.

Cochrane Reviews on TENS for specific chronic pain conditions have suggested that TENS is more effective than placebo TENS, although methodological weaknesses in randomised controlled trials (RCTs) have sometimes hindered definitive conclusions (Bennett 2011; Brosseau 2003; Johnson 2010; Rutjes 2009). Studies carried out on the effect of TENS on neck pain suggested that active TENS may be more effective than placebo TENS (Kroeling 2013). A systematic review on the effect of TENS on cancer pain in adults suggested bone pain on movement may improve in a cancer population on application of TENS, but most of the results remained inconclusive due to a limited number of RCTs included in the review (Hurlow 2012).

Most reviews of TENS therapy are inconclusive at present, which is why a standardised, rigorous search and a Cochrane Review are required in this disease area. This issue is further compounded by the practical need to manage the acute pain crises, as well as chronic pain conditions, experienced by millions of people with SCD worldwide. Current pharmacological therapies produce too many unacceptable side effects, and as already stated, recommendations encourage the use of non-pharmacological methods in SCD pain management. A Cochrane Review of the current evidence regarding the effectiveness of TENS as a complementary therapy for managing pain in people with SCD will allow health professionals and researchers make informed decisions about the use of this treatment.

**O B J E C T I V E S**

To assess the effects of TENS for managing pain in people with SCD who experience pain crises or chronic pain (or both), along with any possible adverse effects.

**M E T H O D S**

**Criteria for considering studies for this review**

**Types of studies**

RCTs. Quasi-RCTs will also be included if sufficient evidence is provided to demonstrate that the treatment and control groups are similar at baseline. In reference to cross-over trials, as we are currently unaware of the long-term effects of these interventions, we are unable to determine whether the effects of the first intervention will interfere with those of the second. In order to avoid introducing this bias into the analysis, we will include only first-arm data from cross-over trials, when available.

**Types of participants**

People with known SCD (SS, SC, Sβ+ and Sβ0, proven by electrophoresis and sickle solubility test, with family studies or DNA tests as appropriate) of all ages and both sexes, in any setting.

**Types of interventions**

We will include all standard modes of TENS which includes biphasic or monophasic electrical current delivered in pulses in high frequency, low intensity or low frequency, high intensity or other standard modes that produce perceptible sensation at the area of application. We will exclude other modes of electrotherapy, TENS that was delivered in intensities that were barely perceptible. Eligible comparisons are:

- TENS with conventional treatment (e.g. analgesics) versus conventional treatment alone;
- TENS versus placebo (sham) TENS;
- TENS versus other non-pharmacological modalities for treatment of pain.

We do not plan to compare different intensities and frequencies of TENS as all standard modes of TENS which produce perceptible sensation at the area of application will be included in this review. Placebo (sham) TENS devices may look exactly similar to active TENS devices, but are deactivated and produce no current or may produce a brief period of stimulation at the beginning which fades out later. Due to the lack of perceptible stimulation in SHAM TENS, blinding of participants to the mode of treatment is almost impossible (Sluka 2013) and this represents a risk of bias to all sham-controlled trials of TENS (Gibson 2015).

**Types of outcome measures**

**Primary outcomes**

1. Pain relief *
2. Pain intensity (as assessed by visual analogue pain scale score (VAS) or other validated assessment tools for measuring pain intensity during the use of TENS)

3. Frequency of pain episodes

* We aim to present data at two to four weeks and after four weeks post intervention. For long-term usage (e.g. for a period of one month) we will consider the outcome measures up to three months. We will consider pain relief as moderate (at least 30% pain relief over baseline) or substantial (at least 50% pain relief over baseline) as defined by IMMPACT guidelines (Dworkin 2008).

**Secondary outcomes**

1. Changes in consumption of analgesic and opioids during pain episodes

2. Changes in quality of life (QoL) (as measured by a validated scale)

3. Ability to cope with the activities of daily living (ADL)

4. Adverse effects of the intervention

**Search methods for identification of studies**

We will search for all relevant published and unpublished trials without restrictions on language, year or publication status.

**Electronic searches**

Relevant studies will be identified from the Cystic Fibrosis and Genetic Disorders Group’s Haemoglobinopathies Trials Register, using the search terms: (sickle cell OR (haemoglobinopathies AND general)) AND transcutaneous electrical nerve stimulation [TENS]. The Haemoglobinopathies Trials Register is compiled from electronic searches of the Cochrane Central Register of Controlled Trials (CENTRAL) (updated each new issue of the Cochrane Library) and weekly searches of MEDLINE. Unpublished work is identified by searching the abstract books of five major conferences: the European Haematology Association conference; the British Society for Haematology conference; the American Haematology Annual Scientific Meeting; the Caribbean Health Research Council Meetings; and the National Sickle Cell Disease Program Annual Meeting. For full details of all searching activities for the register, please see the relevant section of the Cochrane Cystic Fibrosis and Genetic Disorders Group’s website.

We will search the following databases (Appendix 2):

- Embase (Ovid, 1974 onwards);

In addition, we will search the following trial registries and other resources (Appendix 2):

- US National Institutes of Health Ongoing Trials Register, ClinicalTrials.gov (https://clinicaltrials.gov);
- WHO ICTRP register (http://apps.who.int/trialsearch);
- ISRCTN (http://www.isrctn.com);
- Google Scholar (https://scholar.google.co.uk).

Regarding our use of Google Scholar, we will perform a Google Scholar Advanced search, sort the results based on relevance, and screen the first 100 search results for relevant studies.

**Searching other resources**

For assistance in identifying ongoing or unpublished studies, we will contact study authors who have conducted prominent research in the relevant field regarding their ongoing studies or other relevant papers which may be eligible for inclusion.

We will search research papers which cannot be directly included in this review (observational studies, systematic and narrative reviews, conference reports, etc.) for the citations of relevant studies which can be included. These papers will then be sought and assessed for possible inclusion.

Organisations that we will attempt to contact to request suggestions for studies are:

- NCCIH formerly known as NCCAM;
- Foundation for Alternative and Integrative Medicine;
- American Alternative Medical Association;
- The Complementary and Natural Healthcare council;
- International Alternative Medical Association;
- The Association for Applied Psychophysiology and Biofeedback (formerly the Biofeedback Society of America).

Regarding grey literature, studies have shown that published studies often overestimate outcomes, compared to grey literature articles (Hopewell 2007). Moreover, exclusion of grey literature can result in systematic error, thus seriously threatening the validity of a systematic review (McAuley 2000). Therefore, to avoid this risk of publication bias, we will search grey literature databases in our attempt to identify relevant studies and authors from conference proceedings. We propose to search the following databases (recommended in the Cochrane Handbook For Systematic Reviews of Interventions) for unpublished reports or articles which may be appropriate for inclusion in this systematic review (Higgins 2011a):

- OpenGrey (www.opengrey.eu);
- PsychEXTRA (www.apa.org/psychextra);
- The Grey Literature Report (http://greylit.org);
- The Agency for Healthcare Research and Quality (www.ahrq.gov);

**Data collection and analysis**
**Selection of studies**

Two review authors (SP, MG) will independently assess the eligibility of the trials identified by the literature searches by completing a trial selection form that will be designed in accordance with the inclusion criteria. Each author will independently evaluate each title for inclusion. If we do not find the relevant information in the abstract, we will retrieve the relevant full text report(s), if published, in order to complete this task. The authors will select the trials approved by both authors for inclusion in the review. In the case of any discrepancies relating to eligibility, a third author (SKB) will arbitrate. We will tabulate the excluded trials under 'Characteristics of excluded studies' and reasons will be given for the exclusion. The review authors will be unmasked to the trial authors, institutions and trial results during their assessments. We will produce a PRISMA chart as a systematic illustration of the entire trial selection process.

**Data extraction and management**

Two review authors (SP, SM) will independently and simultaneously extract data from the selected articles and this will be verified by two or three review authors with an aim to resolve any disagreements by discussion and consensus. We will extract data using a standardised, pre-tested data extraction form. We will design the data extraction form through a collaboration of the review authors, and then pilot test this using a sample RCT and a quasi-RCT to ensure practical functionality. We will extract the following information from the included studies.

1. **Trial characteristics and source**
   - Trial identifier (ID) - to be created by the review author
   - Report ID - to be created by the review author
   - Citation
   - Contact details

2. **Methodology**
   - Trial design
   - Trial time and duration
   - Setting
   - Randomisation
   - Allocation sequence concealment
   - Type of blinding used
   - Concerns about bias
   - Intention-to-treat analysis

3. **Participants**
   - Total number
   - Eligibility criteria
   - Age and gender of participants

4. **Interventions (TENS and variants)**
   - Total number of intervention groups

   **For each intervention and comparison group of interest**
   - Electrode position
   - Professional discipline of the clinician delivering TENS
   - Frequency and intensity of the electrical current applied through the TENS device
   - Frequency of administration
   - Duration of administration
   - Co-intervention(s)

5. **Outcome measures**

   **For each outcome of interest**
   - Outcome definition
   - Units of measurement (if relevant)
   - For scales, state upper and lower limits, and the interpretation of the scale

6. **Results**

   **For each outcome of interest**
   - Sample size
   - Missing participants
   - Summary data for each intervention group (mean and standard deviation for continuous data, 2 x 2 contingency table for dichotomous data, etc.)

**Assessment of risk of bias in included studies**

Two review authors (RD, SM) will independently assess the risk of bias of the included studies by using the criteria outlined in chapter 8 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011b). Each study will be assessed according to the following five components.

1. Random sequence generation (selection bias)
2. Allocation concealment (selection bias)
3. Masking (blinding) of participants and personnel (performance bias), and masking of outcome assessment
4. Incomplete outcome data (attrition bias) through withdrawals, dropouts and protocol deviations; and
5. Selective reporting bias
We will also assess for any other sources of bias as reported in the Cochrane Handbook for Systematic Reviews of Interventions (bias related to the specific study design, early or abrupt end of studies, fraudulent studies) (Higgins 2011b). For each of the mentioned components, we will assign judgements of either low, unclear or high risk of bias.
We will record the results in the standard table provided in the Review Manager software (RevMan 2014), and will summarize the findings in a ‘Risk of bias’ table or graph. We aim to resolve any concerns or issues by discussion with a third review author (ALA). We will address the implications of the ‘Risk of bias’ assessment in the discussion section.

Measures of treatment effect
We will analyse and present dichotomous data, such as need for daily analgesic consumption between pain events, and ability to cope with ADL using the risk ratios (RR) with 95% confidence intervals (CIs). We will report adverse effects of the intervention with 99% CI to avoid errors due to multiple statistical testing.
We will analyse and present continuous data, such as dose of analgesic consumption between pain events, pain relief and pain intensity as assessed by visual analogue pain scale score (on a scale of 0 to 10), improvements in quality of life (QoL), using the mean differences (MD) (if outcomes are measured using the same scales) along with their 95% CIs. If outcomes are measured using different scales, we will use the standardised MD (SMD) and corresponding 95% CIs.
We will analyse and present count data, such as frequency of pain episodes using the MD, which they will calculate by comparing the difference in the mean number of events in the intervention group as compared to the control group. If they are rare events, we will present the results using the rate ratio with 95% CIs.
Where meta-analysis is not possible, we will present a narrative summary along with tabulated data.

Unit of analysis issues
The unit of analysis in this review will be the individual with SCD. Results of any identified cluster-randomised studies will be reported separately.
Regarding cross-over trials, as we are currently unaware of the long-term effects of these interventions, we are unable to determine whether the effects of the first intervention will interfere with those of the second. In order to avoid introducing this bias into the analysis, we will include only first-arm data from cross-over trials, when available.
If we identify trials with multiple treatment arms, we will only include those treatment arms whose parameters are minimally different from other included trials.

Dealing with missing data
We will contact trial authors to request access to the missing data regarding methods, participants, interventions and outcomes. In cases of missing data due to participant drop out we will conduct a primary analysis based on participants for whom complete data are available, provided that the total number of randomised participants and the number of dropouts to follow-up are well documented. We assume that missing outcomes will not be a problem if loss-to-follow-up is well documented, and is unrelated to outcomes in both trial arms, as per chapter 16 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011a). However, if the reasons for why the data are missing are not available, we will document the possible effects of the missing participants through a sensitivity analysis.

Assessment of heterogeneity
In order to deal with clinical heterogeneity, studies that examine similar interventions will be pooled together. We will perform separate analyses for TENS compared to conventional treatment and TENS compared to placebo TENS or other non-pharmacological treatment. If we identify substantial (or higher) heterogeneity, and provided there are sufficient data, then we will undertake subgroup analyses according to the pre-planned comparisons described in the section ‘Subgroup analysis and investigation of heterogeneity’. We will use the Chi² test for assessing heterogeneity (significance level: P < 0.1). We will quantify the degree of heterogeneity using the I² statistic (Deeks 2008). The guidelines for interpretation of the I² values will be as follows.
- 0% to 40% indicates unimportant levels of heterogeneity
- 30% to 60% indicates moderate heterogeneity
- 50% to 90% indicates substantial heterogeneity
- 75% to 100% indicates considerable heterogeneity
We will also consider a visual inspection of the forest plot to identify whether CIs overlap.

Assessment of reporting biases
As we anticipate the inclusion of trials from the grey literature, it is particularly important for us to conduct an assessment of publication bias. If we identify at least 10 trials for inclusion in a meta-analysis, we will explore potential publication bias by generating a funnel plot and performing Egger’s test to determine the degree of asymmetry (Egger 1997). If the included trials differ in sample size then we will visually inspect the funnel plots to explore the possibility of reporting biases. The results of Egger’s test will also be interpreted cautiously due to the presence of many limitations in quantifying possible reporting biases (Moore 2008). We will address the implications of the publication bias assessment on the review findings in the discussion section.
**Data synthesis**

We will synthesize the quantitative data compiled using the data extraction forms using a meta-analysis. We will use continuous data to calculate a MD or SMD for use in the meta-analysis, depending on the scales of measurement used in the trials (according to the reasoning in ‘Measures of treatment effect’). We will calculate the appropriate measure of association (e.g. RR) for estimation of relative risk using categorical data. The summary measures will be pooled as appropriate, according to the scales used in different trials. We will calculate the I² statistic to determine statistical heterogeneity, and thus determine whether a fixed-effect model (negligible heterogeneity), or a random-effects model (non-negligible heterogeneity) should be used for the meta-analysis (DerSimonian 1986). The results of the meta-analysis will be reported as pooled effect estimates, stated with 95% CIs and illustrated graphically in a forest plot.

If meta-analysis cannot be undertaken for a particular outcome (due to an insufficient number of studies, or any other reason), we will include reasoning for this, as well as a narrative discussion of the available evidence relevant to the outcome variable in question.

**Subgroup analysis and investigation of heterogeneity**

If we identify substantial (or higher) statistical heterogeneity we plan the following subgroup analysis investigating the possible effect of TENS based on:

- age groups (below 18 years of age, 18 years and over);
- gender (male, female);
- stimulation parameters (e.g. high stimulation frequency with low intensity, low frequency with a high stimulus intensity);
- frequency of administration of TENS (e.g. daily or not on a daily basis);
- duration of treatment with TENS (e.g. 30-minute sessions or more than 30 minutes).

**Sensitivity analysis**

We will assess the robustness of our findings by performing sensitivity analyses according to Cochrane recommendations where appropriate (Deeks 2011). If there are sufficient comparable trials, i.e. 10 or more, we will perform sensitivity analyses to study the effect of excluding trials with high risks of bias due to inadequate allocation of concealment, blinding, randomisation method or level of dropouts. Furthermore, we will also consider the impact of using a fixed-effect model compared to a random-effects model.

**Summary of findings table**

We will use the GRADE approach to create a ‘Summary of findings’ table, as suggested in chapters 11 and 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Schünemann 2011a; Schünemann 2011b). The table will present the trial population and setting, the type of intervention and control group, the outcome measures listed below and an assessment of the evidence quality (as measured by the GRADE approach).

We will use the GRADE approach to rate the quality of the evidence as ‘high’, ‘moderate’, ‘low’, or ‘very low’ using the five GRADE considerations.

1. Risk of bias: serious or very serious
2. Inconsistency: serious or very serious
3. Indirectness: serious or very serious
4. Imprecision: serious or very serious
5. Publication bias: likely or very likely

We will generate a separate ‘Summary of findings’ table for each comparison with the following outcomes:

- pain relief;
- pain intensity as assessed by VAS or any other validated pain score;
- frequency of pain episodes;
- changes in consumption of analgesics and opioids during pain episodes;
- changes in QoL (as measured by a validated scale);
- changes in ability to cope with the ADL;
- adverse effects of the intervention.

**Acknowledgements**

We would like to thank:

Tracey Remmington, Managing Editor, Cochrane Cystic Fibrosis and Genetic Disorders Review Group for providing guidance in drafting the protocol;

Sarah Nevitt, Group Statistician, Cochrane Cystic Fibrosis and Genetic Disorders Review Group for providing guidance in drafting the protocol;

Natalie Hall, Information Specialist, Cochrane Cystic Fibrosis and Genetic Disorders Review Group for comments on the search strategy.

We are very grateful to Professor Datuk Dr Abdul Razzak Chief Executive of Melaka-Manipal Medical College, Malaysia and Professor Dr Jaspal Singh, Dean, Faculty of Medicine, Melaka-Manipal Medical College, Malaysia for their constant support, constructive comments and encouragement in writing this protocol.

This project was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the Cochrane Cystic Fibrosis and Genetic Disorders Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, NHS or the Department of Health.
Additional references

American Pain Society Guidelines 1999

Ballas 2005

Ballas 2012

Ballas 2014

Barbedo 1974

Bennett 2011

Brosseau 2003

Brozovic 1987

Buchanan 2005

David 2010

Deeks 2008

Deeks 2011

DerSimonian 1986

DeSantana 2008

Dworkin 2008

Egger 1997

Gibson 2015

Higgins 2011a

Higgins 2011b

Hopewell 2007

Hurlow 2012
Hurlow A, Bennett MI, Robb KA, Johnson MI, Simpson KH, Oxberry SG. Transcutaneous electric nerve stimulation...

**Johnson 2010**

**Kaye 2015**

**Kocyigit 2012**

**Kroeling 2013**

**McAuley 2000**

**Melzack 1965**

**Milne 2004**

**Moore 2008**

**Neville 2011**

**Nicola 2009**

**Platt 1991**

**RevMan 2014 [Computer program]**

**Rutjes 2009**

**Sluka 2013**

**Smith 2005**

**Stinson 2003**

**Sunshine 1996**

**Weatherall 2001**

**WHO 2015**

* Indicates the major publication for the study
Appendix 1. Glossary

<table>
<thead>
<tr>
<th>Term</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Afferent input</td>
<td>Information from our sensory organs (e.g. eye, skin) transmitted as input to the central nervous system (brain, spinal cord)</td>
</tr>
<tr>
<td>Avascular necrosis</td>
<td>Cellular death of bone components due to interruption of the blood supply; the bone structures then collapse, resulting in bone destruction, pain, and loss of joint function</td>
</tr>
<tr>
<td>Endogenous</td>
<td>Originating or developing from within the body.</td>
</tr>
<tr>
<td>Haemolysis</td>
<td>The destruction of red blood cells which leads to the release of hemoglobin from within the red blood cells into the blood plasma</td>
</tr>
<tr>
<td>Hypersplenism</td>
<td>A condition in which the spleen becomes increasingly active and then rapidly removes the blood cells</td>
</tr>
<tr>
<td>Neuropathic</td>
<td>Due to disease of nerves.</td>
</tr>
<tr>
<td>Nociceptive</td>
<td>Of, relating to, or denoting, pain arising from the stimulation of nerve cells (often as distinct from that arising from damage or disease in the nerves themselves)</td>
</tr>
<tr>
<td>Non-invasive</td>
<td>Not requiring the introduction of instruments into the body.</td>
</tr>
<tr>
<td>Pharmacogenomics</td>
<td>The use of human genetic variations to optimise the discovery and development of drugs and the treatment of patients</td>
</tr>
<tr>
<td>Presynaptic inhibition</td>
<td>Refers to a decrease of transmitter release at central synapses</td>
</tr>
<tr>
<td>TIA</td>
<td>Transient ischaemic attack caused by a temporary disruption in the blood supply to part of the brain</td>
</tr>
</tbody>
</table>

Appendix 2. Electronic searches

<table>
<thead>
<tr>
<th>Database/Resource</th>
<th>Strategy</th>
</tr>
</thead>
<tbody>
<tr>
<td>PubMed (1946 onwards)</td>
<td>(sickle OR &quot;Anemia, Sickle Cell&quot;[Mesh]) AND (&quot;Transcutaneous electric&quot; OR &quot;Transcutaneous electrical&quot; OR &quot;Transcutaneous Electric Nerve Stimulation&quot;[Mesh])</td>
</tr>
<tr>
<td>Embase (Ovid 1974 - to present)</td>
<td>1 exp Sickle Cell Anemia/ 2 sickle.tw. 3 1 OR 2 4 Transcutaneous electric* nerv* stimulation.tw.</td>
</tr>
</tbody>
</table>
Continued

| 5 TENS.tw. | 6 Transcutaneous Electrical Nerve Stimulation/ 7 (4 OR 5 OR 6) 8 (3 AND 7) |
| Clinicaltrials.gov | [ADVANCED SEARCH] STUDY TYPE: Interventional Studies CONDITIONS: sickle INTERVENTIONS: transcutaneous OR TENS |
| WHO ICTRP | Two separate searches will be carried out: SEARCH 1: sickle AND transcutaneous SEARCH 2: sickle AND TENS |
| ISRCTN Registry | [ADVANCED SEARCH] CONDITION: sickle INTERVENTIONS: transcutaneous OR TENS |
| Google Scholar | sickle AND ("transcutaneous electric" OR "transcutaneous electrical" OR tens) NOTE: The results will be sorted by "relevance" and the first 100 results screened for relevant studies |
| Grey Literature Databases | Two separate searches of each database will be carried out: SEARCH 1: sickle AND transcutaneous SEARCH 2: sickle AND TENS |

**CONTRIBUTIONS OF AUTHORS**

The following potential contributions of authors to each section of the review are described below.

- Conceiving the review: Cochrane Cystic Fibrosis and Genetic Disorders Review Group
- Designing the review: SP, RD, MG
- Coordinating the review: SP, RD
- Writing the background, objectives and inclusion criteria sections: SP, MG
- Data collection for the review: SP, MG
- Designing search strategies: SP, ALA, SM, MG
- Undertaking searches: SP, MG, SR
- Screening search results: SP, MG
- Organizing retrieval of papers: SP, MG, SM
- Screening retrieved papers against eligibility criteria: SP, MG, UAY
- Appraising quality of papers: SKB
- Extracting data from papers: SP, SM
- Writing to authors of papers for additional information: SP, MG
Providing additional data about papers: Cochrane Cystic Fibrosis and Genetic Disorders Review Group

Obtaining and screening data on unpublished studies: SP, MG

Data management for the review: SM, ALA

Entering data into RevMan: SP, SM, MG, ALA

Analysis of data: SP, SM, MG, ALA

Interpretation of data: SP, SM, MG, ALA

Providing a methodological perspective: ALA, SP

Providing a clinical perspective: SKB, UAY

Writing the review (or protocol): SP, MG

Providing general advice on the review: SKB, UAY

**DECLARATIONS OF INTEREST**

All authors: none known.

**SOURCES OF SUPPORT**

**Internal sources**

- University of Liverpool, UK.

**External sources**

- The National Institute for Health Research (NIHR), UK. United Kingdom Cochrane Centre, UK.